PMID- 36413679
OWN - NLM
STAT- MEDLINE
DCOM- 20221124
LR  - 20231202
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Print)
IS  - 0277-3732 (Linking)
VI  - 45
IP  - 12
DP  - 2022 Dec 1
TI  - Evaluation of 5 Fraction Stereotactic Body Radiation Therapy (SBRT) for Osseous 
      Renal Cell Carcinoma Metastases.
PG  - 501-505
LID - 10.1097/COC.0000000000000952 [doi]
AB  - OBJECTIVES: The best fractionation for stereotactic body radiotherapy (SBRT) in 
      renal cell carcinoma (RCC) metastases has not been well defined. In addition, the 
      literature on outcomes using 5-fraction SBRT in the setting of osseous metastases 
      has not been well reported. MATERIALS AND METHODS: Thirty-nine patients with 69 
      RCC osseous metastases were treated using 5-fraction SBRT at a single institution 
      using 2 dose-fractionation schemes. Overall survival and local-control (LC) 
      outcomes of the 2 fractionation schemes were studied using Kaplan-Meier curves. 
      RESULTS: Of the 69 lesions included in the study, 20 were treated with 30 grays 
      (Gy) in 5 fractions and 49 were treated with 40 Gy in 5 fractions. The median age 
      of patients at diagnosis was 58.4 years. The 1-year LC rate for all treated 
      lesions was 85.5% (59/69) with an LC of 90% (18/20) for lesions receiving 30 Gy 
      and 83.7% (41/49) in lesions receiving 40 Gy. There was no statistically 
      significant difference in 1-year LC rate between the 2 fractionation schemes 
      (P-value, 0.553). CONCLUSIONS: Patients with osseous RCC metastases undergoing 5 
      fractions of SBRT had favorable LC outcomes. There was no difference in survival 
      or LC between the 40 Gy and 30 Gy treatment arms.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Dove, Austin P H
AU  - Dove APH
AUID- ORCID: 0000-0002-2100-9536
AD  - Department of Radiation Oncology and Department of Cancer Biology.
FAU - Wells, Alex
AU  - Wells A
AD  - School of Medicine, Vanderbilt University Medical Center, Nashville, TN.
FAU - Gong, Wu
AU  - Gong W
AD  - Department of Biostatistics.
FAU - Liu, Dandan
AU  - Liu D
AD  - Department of Biostatistics.
FAU - Kirschner, Austin N
AU  - Kirschner AN
AD  - Department of Radiation Oncology and Department of Cancer Biology.
LA  - eng
GR  - UL1 TR002243/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20221114
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - *Carcinoma, Renal Cell/secondary
MH  - *Radiosurgery/adverse effects
MH  - Dose Fractionation, Radiation
MH  - *Bone Neoplasms/radiotherapy
MH  - *Kidney Neoplasms/pathology
PMC - PMC9699181
MID - NIHMS1841022
COIS- The authors declare no conflicts of interest.
EDAT- 2022/11/23 06:00
MHDA- 2022/11/25 06:00
PMCR- 2023/12/01
CRDT- 2022/11/22 15:22
PHST- 2022/11/22 15:22 [entrez]
PHST- 2022/11/23 06:00 [pubmed]
PHST- 2022/11/25 06:00 [medline]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 00000421-202212000-00003 [pii]
AID - 10.1097/COC.0000000000000952 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2022 Dec 1;45(12):501-505. doi: 10.1097/COC.0000000000000952. 
      Epub 2022 Nov 14.